Replies to post #142890 on Elite Pharmaceuticals Inc (ELTP)

[elichen]

Mazeppa--link

http://m.seekingalpha.com/article/2859876-elite-pharmaceuticals-is-well-positioned-to-address-7b-abuse-deterrent-opioid-market?source=email_rt_article_readmore&app=1&auth_param=eb8ok:1ackc3v:052decadd22b51bfc97d5e2a02cc59bc&uprof=51p

[no2koolaid]

I see that the link to the story was provided, but there is more you should be aware of about Seeking Alpha. For that, I have another link for you to review...

http://seekingalpha.com/page/about_us

As to SAs audience, while you can, once again, read for yourself, for anyone interested in the short version (no pun intended), SA and Yahoo discontinued their relationship late last year (just another example of Yahoos troubles). However, SA is most credible, as it is distributed to some notable media sites including: CNBC, MSN Money, TheStreet, Marketwatch and about 7 MILLION MONTHLY ONLINE VISITORS AND SUBSCRIBERS. While I agree the overall media visibility for Elite has been much too limited, if patents and trials are any indication (and they statistically correlate to success) Elite has the tech to win a notable segment of the $7 B opioid pain med market mentioned.

Also noted in the SA article was the $50 B global pain med market, but what was not mentioned was why there is a 3% CAGR in the market in the US and near 5% globally, including Asia. The reason is fairly simple and, in addition to the aging baby boomers, there is a more literate and growing global middle class. If we add to the mix the decision by larger pharma firms to buy companies with novel drugs rather than invest in R&D, we see the increasing M&A activity that industry analysts say shows no signs of abating. Because it is clear that Elite's p/s is being gamed, we shareholders should be pleased that Elite has a completed valuation that would serve as a starting point for negotiations in any acquisition discussion. And, as I said before to the questions about whether the valuation was real or imagined, the fact is, if an investigating body looked into the question of the valuation because of suspected impropriety, they would easily and quickly tie an invoice from Elite to the company that did the valuation. And, Nasrat, Carter Ward, and every member of Elite's senior management knows that to be true because it is basic fundamental accounting!